The trial compared AI-guided and standard physician-guided dietary supplement (DS) prescriptions for lowering LDL cholesterol (LDL-C) in hypercholesterolemic patients. The AI system used genetic, metabolic, and clinical data to personalize DS regimens, hypothesizing superior efficacy over traditional methods. This 3-month randomized, controlled trial involved adults aged 40-75 with specific LDL-C levels, excluding those with significant health risks. Participants were divided into a control group with physician-guided DS and an AI-guided group. The AI system from Triangel Scientific provided dynamic, personalized recommendations. Baseline and follow-up measurements included lipid profiles and adherence assessments. The AI-guided group showed significantly greater LDL-C reduction and improvement in other lipid markers. The study concluded that AI-guided DS prescriptions are more effective, suggesting a promising future for AI in personalized cholesterol management.

Inclusion Criteria:

• Age between 40 and 75 years.
• LDL-C level between 70 and 190 mg/dL, confirmed in at least two sequential checks conducted within the last six months prior to signing the consent form.

Exclusion Criteria:

• Personal history of cardiovascular disease or high risk (≥ 20%).

  • Triglycerides (TG) ≥ 400 mg/dL.
  • Body Mass Index (BMI) ≥ 35 kg/m²
  • Use of lipid-lowering drugs or supplements affecting lipid metabolism within the last three months.
  • Diabetes mellitus.
  • Known severe or uncontrolled thyroid, liver, renal, or muscle diseases.